nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B1—breast cancer	0.248	0.502	CbGaD
Valsartan—AGTR1—breast cancer	0.199	0.403	CbGaD
Valsartan—SLCO1B3—Paclitaxel—breast cancer	0.0485	0.17	CbGbCtD
Valsartan—ALB—breast cancer	0.0472	0.0953	CbGaD
Valsartan—SLCO1B3—Docetaxel—breast cancer	0.035	0.123	CbGbCtD
Valsartan—CYP2C9—Anastrozole—breast cancer	0.032	0.112	CbGbCtD
Valsartan—SLCO1B1—Irinotecan—breast cancer	0.0279	0.0974	CbGbCtD
Valsartan—SLCO1B3—Methotrexate—breast cancer	0.0253	0.0885	CbGbCtD
Valsartan—CYP2C9—Idarubicin—breast cancer	0.0243	0.0849	CbGbCtD
Valsartan—ALB—Irinotecan—breast cancer	0.0153	0.0533	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—breast cancer	0.0147	0.0515	CbGbCtD
Valsartan—ALB—Fluorouracil—breast cancer	0.0146	0.0512	CbGbCtD
Valsartan—CYP2C9—Capecitabine—breast cancer	0.0133	0.0465	CbGbCtD
Valsartan—CYP2C9—Tamoxifen—breast cancer	0.0107	0.0374	CbGbCtD
Valsartan—CYP2C9—Paclitaxel—breast cancer	0.00833	0.0291	CbGbCtD
Valsartan—ALB—Methotrexate—breast cancer	0.00807	0.0282	CbGbCtD
Valsartan—CYP2C9—Fluorouracil—breast cancer	0.00789	0.0276	CbGbCtD
Valsartan—Tasosartan—AGTR2—breast cancer	0.00118	0.231	CrCbGaD
Valsartan—SLCO1B1—mammary gland—breast cancer	0.000825	0.108	CbGeAlD
Valsartan—AGTR1—nipple—breast cancer	0.000716	0.0938	CbGeAlD
Valsartan—Forasartan—AGTR1—breast cancer	0.000676	0.132	CrCbGaD
Valsartan—ALB—mammary gland—breast cancer	0.000667	0.0875	CbGeAlD
Valsartan—SLCO1B3—pituitary gland—breast cancer	0.000645	0.0845	CbGeAlD
Valsartan—SLCO1B3—endocrine gland—breast cancer	0.000499	0.0654	CbGeAlD
Valsartan—AGTR1—epithelium—breast cancer	0.000482	0.0632	CbGeAlD
Valsartan—Irbesartan—JUN—breast cancer	0.000434	0.0848	CrCbGaD
Valsartan—Olmesartan—SLCO1B1—breast cancer	0.000431	0.0844	CrCbGaD
Valsartan—CYP2C9—mammary gland—breast cancer	0.000417	0.0546	CbGeAlD
Valsartan—Tasosartan—AGTR1—breast cancer	0.000409	0.0801	CrCbGaD
Valsartan—AGTR1—pituitary gland—breast cancer	0.000391	0.0512	CbGeAlD
Valsartan—AGTR1—adipose tissue—breast cancer	0.000389	0.051	CbGeAlD
Valsartan—AGTR1—female reproductive system—breast cancer	0.000358	0.0469	CbGeAlD
Valsartan—AGTR1—adrenal gland—breast cancer	0.000349	0.0458	CbGeAlD
Valsartan—Olmesartan—AGTR1—breast cancer	0.000346	0.0677	CrCbGaD
Valsartan—SLCO1B1—female reproductive system—breast cancer	0.000341	0.0447	CbGeAlD
Valsartan—AGTR1—endocrine gland—breast cancer	0.000303	0.0397	CbGeAlD
Valsartan—SLCO1B1—endocrine gland—breast cancer	0.000289	0.0379	CbGeAlD
Valsartan—ALB—adrenal gland—breast cancer	0.000269	0.0353	CbGeAlD
Valsartan—Irbesartan—AGTR1—breast cancer	0.000269	0.0526	CrCbGaD
Valsartan—Candesartan—AGTR1—breast cancer	0.000269	0.0526	CrCbGaD
Valsartan—Losartan—SLCO1B1—breast cancer	0.000216	0.0423	CrCbGaD
Valsartan—AGTR1—lymph node—breast cancer	0.000209	0.0274	CbGeAlD
Valsartan—Losartan—AGTR1—breast cancer	0.000173	0.0339	CrCbGaD
Valsartan—CYP2C9—female reproductive system—breast cancer	0.000172	0.0226	CbGeAlD
Valsartan—ALB—lymph node—breast cancer	0.000162	0.0212	CbGeAlD
Valsartan—CYP2C9—endocrine gland—breast cancer	0.000146	0.0191	CbGeAlD
Valsartan—Irbesartan—PTGS1—breast cancer	0.000125	0.0245	CrCbGaD
Valsartan—Candesartan—PTGS1—breast cancer	0.000125	0.0245	CrCbGaD
Valsartan—Tasosartan—CYP3A4—breast cancer	0.000111	0.0217	CrCbGaD
Valsartan—Irbesartan—CYP2D6—breast cancer	8.51e-05	0.0166	CrCbGaD
Valsartan—Irbesartan—CYP3A4—breast cancer	7.3e-05	0.0143	CrCbGaD
Valsartan—Candesartan—ABCB1—breast cancer	6.08e-05	0.0119	CrCbGaD
Valsartan—Losartan—CYP3A4—breast cancer	4.7e-05	0.0092	CrCbGaD
Valsartan—Pharyngitis—Epirubicin—breast cancer	4.38e-05	0.000305	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—breast cancer	4.38e-05	0.000305	CcSEcCtD
Valsartan—Skin disorder—Capecitabine—breast cancer	4.37e-05	0.000305	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—breast cancer	4.36e-05	0.000304	CcSEcCtD
Valsartan—Urticaria—Paclitaxel—breast cancer	4.36e-05	0.000304	CcSEcCtD
Valsartan—Hypotension—Docetaxel—breast cancer	4.34e-05	0.000303	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—breast cancer	4.34e-05	0.000302	CcSEcCtD
Valsartan—Abdominal pain—Paclitaxel—breast cancer	4.34e-05	0.000302	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—breast cancer	4.33e-05	0.000301	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—breast cancer	4.29e-05	0.000299	CcSEcCtD
Valsartan—Anorexia—Capecitabine—breast cancer	4.29e-05	0.000299	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—breast cancer	4.28e-05	0.000298	CcSEcCtD
Valsartan—Vomiting—Mitoxantrone—breast cancer	4.28e-05	0.000298	CcSEcCtD
Valsartan—Vomiting—Irinotecan—breast cancer	4.28e-05	0.000298	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—breast cancer	4.27e-05	0.000297	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—breast cancer	4.26e-05	0.000297	CcSEcCtD
Valsartan—Dizziness—Fluorouracil—breast cancer	4.26e-05	0.000297	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—breast cancer	4.25e-05	0.000296	CcSEcCtD
Valsartan—Rash—Irinotecan—breast cancer	4.24e-05	0.000295	CcSEcCtD
Valsartan—Rash—Mitoxantrone—breast cancer	4.24e-05	0.000295	CcSEcCtD
Valsartan—Dermatitis—Mitoxantrone—breast cancer	4.24e-05	0.000295	CcSEcCtD
Valsartan—Dermatitis—Irinotecan—breast cancer	4.24e-05	0.000295	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Docetaxel—breast cancer	4.24e-05	0.000295	CcSEcCtD
Valsartan—Headache—Irinotecan—breast cancer	4.21e-05	0.000294	CcSEcCtD
Valsartan—Headache—Mitoxantrone—breast cancer	4.21e-05	0.000294	CcSEcCtD
Valsartan—Hypotension—Capecitabine—breast cancer	4.21e-05	0.000293	CcSEcCtD
Valsartan—Insomnia—Docetaxel—breast cancer	4.21e-05	0.000293	CcSEcCtD
Valsartan—Paraesthesia—Docetaxel—breast cancer	4.17e-05	0.000291	CcSEcCtD
Valsartan—Alopecia—Methotrexate—breast cancer	4.17e-05	0.00029	CcSEcCtD
Valsartan—Vomiting—Gemcitabine—breast cancer	4.17e-05	0.00029	CcSEcCtD
Valsartan—Dyspnoea—Docetaxel—breast cancer	4.14e-05	0.000289	CcSEcCtD
Valsartan—Somnolence—Docetaxel—breast cancer	4.13e-05	0.000288	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—breast cancer	4.13e-05	0.000288	CcSEcCtD
Valsartan—Rash—Gemcitabine—breast cancer	4.13e-05	0.000288	CcSEcCtD
Valsartan—Dermatitis—Gemcitabine—breast cancer	4.13e-05	0.000288	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—breast cancer	4.11e-05	0.000286	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—breast cancer	4.1e-05	0.000286	CcSEcCtD
Valsartan—Headache—Gemcitabine—breast cancer	4.1e-05	0.000286	CcSEcCtD
Valsartan—Losartan—ALB—breast cancer	4.1e-05	0.00803	CrCbGaD
Valsartan—Musculoskeletal discomfort—Capecitabine—breast cancer	4.1e-05	0.000286	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—breast cancer	4.1e-05	0.000285	CcSEcCtD
Valsartan—Vomiting—Fluorouracil—breast cancer	4.1e-05	0.000285	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—breast cancer	4.09e-05	0.000285	CcSEcCtD
Valsartan—Dyspepsia—Docetaxel—breast cancer	4.09e-05	0.000285	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—breast cancer	4.08e-05	0.000285	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—breast cancer	4.08e-05	0.000285	CcSEcCtD
Valsartan—Insomnia—Capecitabine—breast cancer	4.07e-05	0.000284	CcSEcCtD
Valsartan—Rash—Fluorouracil—breast cancer	4.06e-05	0.000283	CcSEcCtD
Valsartan—Dermatitis—Fluorouracil—breast cancer	4.06e-05	0.000283	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—breast cancer	4.05e-05	0.000282	CcSEcCtD
Valsartan—Paraesthesia—Capecitabine—breast cancer	4.04e-05	0.000282	CcSEcCtD
Valsartan—Decreased appetite—Docetaxel—breast cancer	4.04e-05	0.000282	CcSEcCtD
Valsartan—Hypersensitivity—Paclitaxel—breast cancer	4.04e-05	0.000282	CcSEcCtD
Valsartan—Headache—Fluorouracil—breast cancer	4.04e-05	0.000281	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—breast cancer	4.03e-05	0.000281	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—breast cancer	4.02e-05	0.00028	CcSEcCtD
Valsartan—Gastrointestinal disorder—Docetaxel—breast cancer	4.01e-05	0.00028	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—breast cancer	4.01e-05	0.00028	CcSEcCtD
Valsartan—Dyspnoea—Capecitabine—breast cancer	4.01e-05	0.00028	CcSEcCtD
Valsartan—Fatigue—Docetaxel—breast cancer	4.01e-05	0.000279	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—breast cancer	4e-05	0.000279	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—breast cancer	4e-05	0.000279	CcSEcCtD
Valsartan—Nausea—Irinotecan—breast cancer	3.99e-05	0.000278	CcSEcCtD
Valsartan—Nausea—Mitoxantrone—breast cancer	3.99e-05	0.000278	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—breast cancer	3.99e-05	0.000278	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—breast cancer	3.98e-05	0.000277	CcSEcCtD
Valsartan—Constipation—Docetaxel—breast cancer	3.98e-05	0.000277	CcSEcCtD
Valsartan—Back pain—Methotrexate—breast cancer	3.97e-05	0.000277	CcSEcCtD
Valsartan—Dyspepsia—Capecitabine—breast cancer	3.96e-05	0.000276	CcSEcCtD
Valsartan—Asthenia—Paclitaxel—breast cancer	3.94e-05	0.000274	CcSEcCtD
Valsartan—Losartan—ABCB1—breast cancer	3.92e-05	0.00766	CrCbGaD
Valsartan—Decreased appetite—Capecitabine—breast cancer	3.91e-05	0.000273	CcSEcCtD
Valsartan—Alopecia—Epirubicin—breast cancer	3.9e-05	0.000272	CcSEcCtD
Valsartan—Nausea—Gemcitabine—breast cancer	3.89e-05	0.000271	CcSEcCtD
Valsartan—Gastrointestinal disorder—Capecitabine—breast cancer	3.89e-05	0.000271	CcSEcCtD
Valsartan—Fatigue—Capecitabine—breast cancer	3.88e-05	0.00027	CcSEcCtD
Valsartan—Pruritus—Paclitaxel—breast cancer	3.88e-05	0.00027	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—breast cancer	3.87e-05	0.00027	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—breast cancer	3.87e-05	0.000269	CcSEcCtD
Valsartan—Constipation—Capecitabine—breast cancer	3.85e-05	0.000268	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—breast cancer	3.84e-05	0.000268	CcSEcCtD
Valsartan—Nausea—Fluorouracil—breast cancer	3.83e-05	0.000267	CcSEcCtD
Valsartan—Gastrointestinal pain—Docetaxel—breast cancer	3.8e-05	0.000265	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—breast cancer	3.79e-05	0.000264	CcSEcCtD
Valsartan—Flatulence—Epirubicin—breast cancer	3.79e-05	0.000264	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—breast cancer	3.76e-05	0.000262	CcSEcCtD
Valsartan—Diarrhoea—Paclitaxel—breast cancer	3.75e-05	0.000261	CcSEcCtD
Valsartan—Back pain—Epirubicin—breast cancer	3.72e-05	0.000259	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—breast cancer	3.71e-05	0.000258	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—breast cancer	3.69e-05	0.000257	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—breast cancer	3.69e-05	0.000257	CcSEcCtD
Valsartan—Vertigo—Methotrexate—breast cancer	3.69e-05	0.000257	CcSEcCtD
Valsartan—Gastrointestinal pain—Capecitabine—breast cancer	3.68e-05	0.000256	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—breast cancer	3.68e-05	0.000256	CcSEcCtD
Valsartan—Abdominal pain—Docetaxel—breast cancer	3.68e-05	0.000256	CcSEcCtD
Valsartan—Dizziness—Paclitaxel—breast cancer	3.63e-05	0.000253	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—breast cancer	3.62e-05	0.000252	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—breast cancer	3.61e-05	0.000251	CcSEcCtD
Valsartan—Cough—Methotrexate—breast cancer	3.58e-05	0.00025	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—breast cancer	3.58e-05	0.000249	CcSEcCtD
Valsartan—Urticaria—Capecitabine—breast cancer	3.58e-05	0.000249	CcSEcCtD
Valsartan—Abdominal pain—Capecitabine—breast cancer	3.56e-05	0.000248	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—breast cancer	3.56e-05	0.000248	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—breast cancer	3.5e-05	0.000244	CcSEcCtD
Valsartan—Chest pain—Methotrexate—breast cancer	3.5e-05	0.000244	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—breast cancer	3.5e-05	0.000244	CcSEcCtD
Valsartan—Myalgia—Methotrexate—breast cancer	3.5e-05	0.000244	CcSEcCtD
Valsartan—Vomiting—Paclitaxel—breast cancer	3.49e-05	0.000243	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—breast cancer	3.48e-05	0.000243	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.47e-05	0.000242	CcSEcCtD
Valsartan—Rash—Paclitaxel—breast cancer	3.46e-05	0.000241	CcSEcCtD
Valsartan—Dermatitis—Paclitaxel—breast cancer	3.46e-05	0.000241	CcSEcCtD
Valsartan—Vertigo—Epirubicin—breast cancer	3.45e-05	0.000241	CcSEcCtD
Valsartan—Syncope—Epirubicin—breast cancer	3.45e-05	0.00024	CcSEcCtD
Valsartan—Back pain—Doxorubicin—breast cancer	3.44e-05	0.00024	CcSEcCtD
Valsartan—Headache—Paclitaxel—breast cancer	3.44e-05	0.000239	CcSEcCtD
Valsartan—Hypersensitivity—Docetaxel—breast cancer	3.43e-05	0.000239	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—breast cancer	3.42e-05	0.000238	CcSEcCtD
Valsartan—Palpitations—Epirubicin—breast cancer	3.4e-05	0.000237	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—breast cancer	3.38e-05	0.000235	CcSEcCtD
Valsartan—Cough—Epirubicin—breast cancer	3.35e-05	0.000234	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—breast cancer	3.35e-05	0.000233	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—breast cancer	3.35e-05	0.000233	CcSEcCtD
Valsartan—Asthenia—Docetaxel—breast cancer	3.34e-05	0.000232	CcSEcCtD
Valsartan—Infection—Methotrexate—breast cancer	3.33e-05	0.000232	CcSEcCtD
Valsartan—Hypersensitivity—Capecitabine—breast cancer	3.32e-05	0.000231	CcSEcCtD
Valsartan—Pruritus—Docetaxel—breast cancer	3.29e-05	0.000229	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—breast cancer	3.29e-05	0.000229	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—breast cancer	3.28e-05	0.000229	CcSEcCtD
Valsartan—Chest pain—Epirubicin—breast cancer	3.27e-05	0.000228	CcSEcCtD
Valsartan—Myalgia—Epirubicin—breast cancer	3.27e-05	0.000228	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—breast cancer	3.27e-05	0.000228	CcSEcCtD
Valsartan—Anxiety—Epirubicin—breast cancer	3.26e-05	0.000227	CcSEcCtD
Valsartan—Nausea—Paclitaxel—breast cancer	3.26e-05	0.000227	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—breast cancer	3.25e-05	0.000227	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.25e-05	0.000226	CcSEcCtD
Valsartan—Asthenia—Capecitabine—breast cancer	3.23e-05	0.000225	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—breast cancer	3.2e-05	0.000223	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—breast cancer	3.19e-05	0.000223	CcSEcCtD
Valsartan—Anorexia—Methotrexate—breast cancer	3.19e-05	0.000223	CcSEcCtD
Valsartan—Syncope—Doxorubicin—breast cancer	3.19e-05	0.000222	CcSEcCtD
Valsartan—Pruritus—Capecitabine—breast cancer	3.18e-05	0.000222	CcSEcCtD
Valsartan—Diarrhoea—Docetaxel—breast cancer	3.18e-05	0.000222	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—breast cancer	3.14e-05	0.000219	CcSEcCtD
Valsartan—Oedema—Epirubicin—breast cancer	3.14e-05	0.000218	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—breast cancer	3.14e-05	0.000218	CcSEcCtD
Valsartan—Hypotension—Methotrexate—breast cancer	3.13e-05	0.000218	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—breast cancer	3.12e-05	0.000218	CcSEcCtD
Valsartan—Infection—Epirubicin—breast cancer	3.12e-05	0.000217	CcSEcCtD
Valsartan—Cough—Doxorubicin—breast cancer	3.1e-05	0.000216	CcSEcCtD
Valsartan—Shock—Epirubicin—breast cancer	3.09e-05	0.000215	CcSEcCtD
Valsartan—Diarrhoea—Capecitabine—breast cancer	3.08e-05	0.000215	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—breast cancer	3.08e-05	0.000214	CcSEcCtD
Valsartan—Dizziness—Docetaxel—breast cancer	3.07e-05	0.000214	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—breast cancer	3.07e-05	0.000214	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—breast cancer	3.05e-05	0.000213	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—breast cancer	3.05e-05	0.000212	CcSEcCtD
Valsartan—Insomnia—Methotrexate—breast cancer	3.03e-05	0.000211	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—breast cancer	3.03e-05	0.000211	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—breast cancer	3.03e-05	0.000211	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—breast cancer	3.03e-05	0.000211	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—breast cancer	3.02e-05	0.00021	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—breast cancer	3.01e-05	0.00021	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.01e-05	0.000209	CcSEcCtD
Valsartan—Anorexia—Epirubicin—breast cancer	2.99e-05	0.000208	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—breast cancer	2.99e-05	0.000208	CcSEcCtD
Valsartan—Somnolence—Methotrexate—breast cancer	2.98e-05	0.000208	CcSEcCtD
Valsartan—Dizziness—Capecitabine—breast cancer	2.98e-05	0.000207	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—breast cancer	2.96e-05	0.000206	CcSEcCtD
Valsartan—Vomiting—Docetaxel—breast cancer	2.96e-05	0.000206	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—breast cancer	2.95e-05	0.000205	CcSEcCtD
Valsartan—Rash—Docetaxel—breast cancer	2.93e-05	0.000204	CcSEcCtD
Valsartan—Hypotension—Epirubicin—breast cancer	2.93e-05	0.000204	CcSEcCtD
Valsartan—Dermatitis—Docetaxel—breast cancer	2.93e-05	0.000204	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—breast cancer	2.91e-05	0.000203	CcSEcCtD
Valsartan—Headache—Docetaxel—breast cancer	2.91e-05	0.000203	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—breast cancer	2.9e-05	0.000202	CcSEcCtD
Valsartan—Oedema—Doxorubicin—breast cancer	2.9e-05	0.000202	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—breast cancer	2.89e-05	0.000202	CcSEcCtD
Valsartan—Fatigue—Methotrexate—breast cancer	2.89e-05	0.000201	CcSEcCtD
Valsartan—Infection—Doxorubicin—breast cancer	2.88e-05	0.000201	CcSEcCtD
Valsartan—Vomiting—Capecitabine—breast cancer	2.86e-05	0.000199	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—breast cancer	2.86e-05	0.000199	CcSEcCtD
Valsartan—Shock—Doxorubicin—breast cancer	2.85e-05	0.000199	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—breast cancer	2.85e-05	0.000198	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—breast cancer	2.84e-05	0.000198	CcSEcCtD
Valsartan—Rash—Capecitabine—breast cancer	2.84e-05	0.000198	CcSEcCtD
Valsartan—Insomnia—Epirubicin—breast cancer	2.84e-05	0.000198	CcSEcCtD
Valsartan—Dermatitis—Capecitabine—breast cancer	2.84e-05	0.000198	CcSEcCtD
Valsartan—Headache—Capecitabine—breast cancer	2.82e-05	0.000196	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—breast cancer	2.82e-05	0.000196	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—breast cancer	2.82e-05	0.000196	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—breast cancer	2.8e-05	0.000195	CcSEcCtD
Valsartan—Somnolence—Epirubicin—breast cancer	2.79e-05	0.000194	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—breast cancer	2.77e-05	0.000193	CcSEcCtD
Valsartan—Nausea—Docetaxel—breast cancer	2.76e-05	0.000192	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—breast cancer	2.76e-05	0.000192	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—breast cancer	2.74e-05	0.000191	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—breast cancer	2.73e-05	0.00019	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—breast cancer	2.71e-05	0.000189	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—breast cancer	2.71e-05	0.000189	CcSEcCtD
Valsartan—Fatigue—Epirubicin—breast cancer	2.7e-05	0.000188	CcSEcCtD
Valsartan—Constipation—Epirubicin—breast cancer	2.68e-05	0.000187	CcSEcCtD
Valsartan—Nausea—Capecitabine—breast cancer	2.67e-05	0.000186	CcSEcCtD
Valsartan—Urticaria—Methotrexate—breast cancer	2.66e-05	0.000185	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—breast cancer	2.65e-05	0.000185	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.64e-05	0.000184	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—breast cancer	2.62e-05	0.000183	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—breast cancer	2.61e-05	0.000182	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—breast cancer	2.59e-05	0.00018	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—breast cancer	2.58e-05	0.00018	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—breast cancer	2.56e-05	0.000179	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—breast cancer	2.55e-05	0.000178	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—breast cancer	2.52e-05	0.000176	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—breast cancer	2.51e-05	0.000175	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—breast cancer	2.5e-05	0.000174	CcSEcCtD
Valsartan—Urticaria—Epirubicin—breast cancer	2.49e-05	0.000174	CcSEcCtD
Valsartan—Constipation—Doxorubicin—breast cancer	2.48e-05	0.000173	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—breast cancer	2.48e-05	0.000173	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—breast cancer	2.47e-05	0.000172	CcSEcCtD
Valsartan—Asthenia—Methotrexate—breast cancer	2.4e-05	0.000167	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—breast cancer	2.37e-05	0.000165	CcSEcCtD
Valsartan—Pruritus—Methotrexate—breast cancer	2.37e-05	0.000165	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—breast cancer	2.31e-05	0.000161	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—breast cancer	2.31e-05	0.000161	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—breast cancer	2.29e-05	0.00016	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—breast cancer	2.29e-05	0.00016	CcSEcCtD
Valsartan—Asthenia—Epirubicin—breast cancer	2.25e-05	0.000157	CcSEcCtD
Valsartan—Pruritus—Epirubicin—breast cancer	2.22e-05	0.000155	CcSEcCtD
Valsartan—Dizziness—Methotrexate—breast cancer	2.22e-05	0.000154	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—breast cancer	2.15e-05	0.000149	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—breast cancer	2.14e-05	0.000149	CcSEcCtD
Valsartan—Vomiting—Methotrexate—breast cancer	2.13e-05	0.000148	CcSEcCtD
Valsartan—Rash—Methotrexate—breast cancer	2.11e-05	0.000147	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—breast cancer	2.11e-05	0.000147	CcSEcCtD
Valsartan—Headache—Methotrexate—breast cancer	2.1e-05	0.000146	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—breast cancer	2.08e-05	0.000145	CcSEcCtD
Valsartan—Dizziness—Epirubicin—breast cancer	2.07e-05	0.000144	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—breast cancer	2.05e-05	0.000143	CcSEcCtD
Valsartan—Vomiting—Epirubicin—breast cancer	1.99e-05	0.000139	CcSEcCtD
Valsartan—Nausea—Methotrexate—breast cancer	1.99e-05	0.000139	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—breast cancer	1.99e-05	0.000138	CcSEcCtD
Valsartan—Rash—Epirubicin—breast cancer	1.98e-05	0.000138	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—breast cancer	1.98e-05	0.000138	CcSEcCtD
Valsartan—Headache—Epirubicin—breast cancer	1.96e-05	0.000137	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—breast cancer	1.92e-05	0.000134	CcSEcCtD
Valsartan—Nausea—Epirubicin—breast cancer	1.86e-05	0.00013	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—breast cancer	1.84e-05	0.000129	CcSEcCtD
Valsartan—Rash—Doxorubicin—breast cancer	1.83e-05	0.000127	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—breast cancer	1.83e-05	0.000127	CcSEcCtD
Valsartan—Headache—Doxorubicin—breast cancer	1.82e-05	0.000127	CcSEcCtD
Valsartan—Nausea—Doxorubicin—breast cancer	1.72e-05	0.00012	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	8.06e-06	0.000128	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAT2—breast cancer	8.05e-06	0.000128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—breast cancer	8e-06	0.000127	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CAV1—breast cancer	7.99e-06	0.000127	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK3—breast cancer	7.99e-06	0.000127	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—breast cancer	7.79e-06	0.000124	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—breast cancer	7.75e-06	0.000123	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCC1—breast cancer	7.75e-06	0.000123	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMMR—breast cancer	7.75e-06	0.000123	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA3—breast cancer	7.75e-06	0.000123	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FN1—breast cancer	7.7e-06	0.000122	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—breast cancer	7.69e-06	0.000122	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—breast cancer	7.68e-06	0.000122	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKBIA—breast cancer	7.61e-06	0.000121	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FN1—breast cancer	7.6e-06	0.000121	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—COMT—breast cancer	7.6e-06	0.000121	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—breast cancer	7.57e-06	0.00012	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH1—breast cancer	7.53e-06	0.000119	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—breast cancer	7.51e-06	0.000119	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARGC1B—breast cancer	7.5e-06	0.000119	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—breast cancer	7.46e-06	0.000118	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ITPR1—breast cancer	7.45e-06	0.000118	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APC—breast cancer	7.37e-06	0.000117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—breast cancer	7.37e-06	0.000117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KIT—breast cancer	7.37e-06	0.000117	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	7.3e-06	0.000116	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	7.3e-06	0.000116	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGF—breast cancer	7.28e-06	0.000116	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—breast cancer	7.28e-06	0.000115	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CAV1—breast cancer	7.27e-06	0.000115	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EGF—breast cancer	7.19e-06	0.000114	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCB1—breast cancer	7.16e-06	0.000114	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA9—breast cancer	7.08e-06	0.000112	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA4—breast cancer	7.08e-06	0.000112	CbGpPWpGaD
Valsartan—ALB—Metabolism—DPYD—breast cancer	7.06e-06	0.000112	CbGpPWpGaD
Valsartan—ALB—Metabolism—MED12—breast cancer	7.06e-06	0.000112	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK3—breast cancer	7.05e-06	0.000112	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMS—breast cancer	7.04e-06	0.000112	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—breast cancer	6.99e-06	0.000111	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PLA2G4A—breast cancer	6.96e-06	0.00011	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NCOR1—breast cancer	6.96e-06	0.00011	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—breast cancer	6.96e-06	0.00011	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDOA—breast cancer	6.95e-06	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	6.92e-06	0.00011	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—breast cancer	6.92e-06	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA2—breast cancer	6.9e-06	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX2—breast cancer	6.9e-06	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX4—breast cancer	6.82e-06	0.000108	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SULT1A1—breast cancer	6.82e-06	0.000108	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—breast cancer	6.76e-06	0.000107	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—breast cancer	6.74e-06	0.000107	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA3—breast cancer	6.74e-06	0.000107	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT2—breast cancer	6.74e-06	0.000107	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—breast cancer	6.71e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A2—breast cancer	6.7e-06	0.000106	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—breast cancer	6.67e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—breast cancer	6.66e-06	0.000106	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—breast cancer	6.66e-06	0.000106	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—IDH1—breast cancer	6.66e-06	0.000106	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA1—breast cancer	6.66e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT2—breast cancer	6.66e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	6.63e-06	0.000105	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—breast cancer	6.6e-06	0.000105	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A1—breast cancer	6.59e-06	0.000105	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAT2—breast cancer	6.59e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—CPT1A—breast cancer	6.56e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCG2—breast cancer	6.56e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTR—breast cancer	6.56e-06	0.000104	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ERCC2—breast cancer	6.54e-06	0.000104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—breast cancer	6.48e-06	0.000103	CbGpPWpGaD
Valsartan—ALB—Metabolism—HPGDS—breast cancer	6.43e-06	0.000102	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—breast cancer	6.41e-06	0.000102	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—breast cancer	6.4e-06	0.000102	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—breast cancer	6.4e-06	0.000101	CbGpPWpGaD
Valsartan—ALB—Metabolism—HBA1—breast cancer	6.39e-06	0.000101	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—breast cancer	6.38e-06	0.000101	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—breast cancer	6.34e-06	0.000101	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—breast cancer	6.33e-06	0.0001	CbGpPWpGaD
Valsartan—ALB—Metabolism—ACHE—breast cancer	6.24e-06	9.9e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—breast cancer	6.24e-06	9.9e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—breast cancer	6.15e-06	9.75e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—breast cancer	6.11e-06	9.7e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—breast cancer	6.04e-06	9.58e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—breast cancer	5.95e-06	9.45e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP17A1—breast cancer	5.91e-06	9.37e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—breast cancer	5.89e-06	9.34e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO1—breast cancer	5.85e-06	9.27e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS1—breast cancer	5.85e-06	9.27e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—breast cancer	5.84e-06	9.26e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	5.82e-06	9.24e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—breast cancer	5.82e-06	9.24e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MDM2—breast cancer	5.8e-06	9.2e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAF1—breast cancer	5.78e-06	9.17e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MED12—breast cancer	5.77e-06	9.16e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—DPYD—breast cancer	5.77e-06	9.16e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RELA—breast cancer	5.76e-06	9.13e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2D6—breast cancer	5.73e-06	9.1e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB2—breast cancer	5.72e-06	9.07e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAF1—breast cancer	5.71e-06	9.06e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDOA—breast cancer	5.69e-06	9.02e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAV1—breast cancer	5.67e-06	8.99e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MTOR—breast cancer	5.64e-06	8.95e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—breast cancer	5.64e-06	8.95e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA2—breast cancer	5.63e-06	8.93e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—breast cancer	5.58e-06	8.85e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA3—breast cancer	5.52e-06	8.76e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A2—breast cancer	5.48e-06	8.69e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—FASN—breast cancer	5.46e-06	8.66e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—BCHE—breast cancer	5.43e-06	8.62e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—breast cancer	5.42e-06	8.6e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	5.42e-06	8.6e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	5.42e-06	8.59e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—breast cancer	5.39e-06	8.55e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	5.39e-06	8.55e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CPT1A—breast cancer	5.37e-06	8.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTR—breast cancer	5.37e-06	8.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG2—breast cancer	5.37e-06	8.52e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC5A5—breast cancer	5.37e-06	8.52e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1B—breast cancer	5.3e-06	8.4e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HPGDS—breast cancer	5.27e-06	8.35e-05	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—breast cancer	5.24e-06	8.31e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HBA1—breast cancer	5.23e-06	8.3e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—breast cancer	5.19e-06	8.24e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A1—breast cancer	5.18e-06	8.23e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NQO1—breast cancer	5.18e-06	8.23e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—breast cancer	5.18e-06	8.22e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—breast cancer	5.16e-06	8.19e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—breast cancer	5.16e-06	8.18e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—breast cancer	5.12e-06	8.12e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—breast cancer	5.11e-06	8.1e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ACHE—breast cancer	5.11e-06	8.1e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—breast cancer	5.09e-06	8.07e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	5.08e-06	8.05e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP3A4—breast cancer	5.06e-06	8.02e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—breast cancer	5.05e-06	8.02e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUN—breast cancer	5.04e-06	8e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	5.03e-06	7.98e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CTNNB1—breast cancer	5e-06	7.94e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1B1—breast cancer	4.97e-06	7.89e-05	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	4.94e-06	7.84e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—breast cancer	4.91e-06	7.78e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—breast cancer	4.89e-06	7.75e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—breast cancer	4.88e-06	7.74e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSP90AA1—breast cancer	4.87e-06	7.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP17A1—breast cancer	4.83e-06	7.67e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS1—breast cancer	4.79e-06	7.59e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO1—breast cancer	4.79e-06	7.59e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK8—breast cancer	4.77e-06	7.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	4.77e-06	7.56e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—breast cancer	4.76e-06	7.55e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA1—breast cancer	4.74e-06	7.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	4.71e-06	7.47e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2D6—breast cancer	4.69e-06	7.44e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—STK11—breast cancer	4.67e-06	7.41e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP19A1—breast cancer	4.67e-06	7.41e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA2—breast cancer	4.61e-06	7.31e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—breast cancer	4.54e-06	7.2e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—breast cancer	4.52e-06	7.18e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—breast cancer	4.48e-06	7.11e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—breast cancer	4.47e-06	7.09e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FASN—breast cancer	4.47e-06	7.09e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BCHE—breast cancer	4.45e-06	7.06e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—breast cancer	4.41e-06	6.99e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC5A5—breast cancer	4.39e-06	6.97e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	4.39e-06	6.96e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—breast cancer	4.36e-06	6.92e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—breast cancer	4.35e-06	6.9e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—COMT—breast cancer	4.34e-06	6.89e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—breast cancer	4.32e-06	6.86e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—breast cancer	4.29e-06	6.8e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—breast cancer	4.26e-06	6.77e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ITPR1—breast cancer	4.26e-06	6.75e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A1—breast cancer	4.24e-06	6.73e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NQO1—breast cancer	4.24e-06	6.73e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK3—breast cancer	4.17e-06	6.61e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.16e-06	6.59e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP3A4—breast cancer	4.14e-06	6.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.12e-06	6.53e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK3—breast cancer	4.12e-06	6.53e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCB1—breast cancer	4.09e-06	6.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1B1—breast cancer	4.07e-06	6.45e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—breast cancer	4.05e-06	6.43e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—breast cancer	4.04e-06	6.41e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMS—breast cancer	4.02e-06	6.38e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—breast cancer	3.99e-06	6.34e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSP90AA1—breast cancer	3.99e-06	6.33e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOR1—breast cancer	3.97e-06	6.3e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—breast cancer	3.97e-06	6.3e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G4A—breast cancer	3.97e-06	6.3e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—breast cancer	3.96e-06	6.29e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—breast cancer	3.96e-06	6.28e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—breast cancer	3.92e-06	6.22e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA1—breast cancer	3.88e-06	6.16e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—STK11—breast cancer	3.83e-06	6.07e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP19A1—breast cancer	3.83e-06	6.07e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—breast cancer	3.81e-06	6.04e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A1—breast cancer	3.77e-06	5.98e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—breast cancer	3.75e-06	5.94e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ERCC2—breast cancer	3.74e-06	5.93e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—breast cancer	3.7e-06	5.87e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.59e-06	5.7e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—breast cancer	3.59e-06	5.7e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—COMT—breast cancer	3.56e-06	5.64e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—breast cancer	3.54e-06	5.62e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—breast cancer	3.51e-06	5.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—breast cancer	3.49e-06	5.54e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ITPR1—breast cancer	3.48e-06	5.53e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—breast cancer	3.44e-06	5.46e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—breast cancer	3.42e-06	5.42e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—breast cancer	3.4e-06	5.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCB1—breast cancer	3.35e-06	5.32e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—breast cancer	3.33e-06	5.28e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMS—breast cancer	3.29e-06	5.22e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—breast cancer	3.29e-06	5.22e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOR1—breast cancer	3.25e-06	5.16e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G4A—breast cancer	3.25e-06	5.16e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—breast cancer	3.25e-06	5.16e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAV1—breast cancer	3.24e-06	5.14e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—breast cancer	3.18e-06	5.05e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—breast cancer	3.15e-06	4.99e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—breast cancer	3.11e-06	4.94e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.09e-06	4.91e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A1—breast cancer	3.08e-06	4.89e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ERCC2—breast cancer	3.06e-06	4.85e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—breast cancer	3.05e-06	4.83e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—breast cancer	2.95e-06	4.68e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—breast cancer	2.93e-06	4.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—breast cancer	2.87e-06	4.56e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—breast cancer	2.81e-06	4.46e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—breast cancer	2.78e-06	4.41e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAV1—breast cancer	2.65e-06	4.21e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—breast cancer	2.59e-06	4.12e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.53e-06	4.02e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—breast cancer	2.45e-06	3.89e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—breast cancer	2.42e-06	3.83e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—breast cancer	2.41e-06	3.83e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—breast cancer	2.26e-06	3.59e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—breast cancer	2.24e-06	3.55e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—breast cancer	2.12e-06	3.37e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—breast cancer	2.1e-06	3.33e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—breast cancer	2e-06	3.18e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—breast cancer	1.97e-06	3.13e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—breast cancer	1.95e-06	3.1e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—breast cancer	1.85e-06	2.94e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—breast cancer	1.83e-06	2.91e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—breast cancer	1.6e-06	2.54e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—breast cancer	1.38e-06	2.19e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—breast cancer	1.13e-06	1.79e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—breast cancer	1.13e-06	1.79e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—breast cancer	9.22e-07	1.46e-05	CbGpPWpGaD
